News & Events

BD Biosciences, a segment of BD (Becton, Dickinson and Company), today announced plans to expand its Treyburn facility in Durham, North Carolina to consolidate and increase U.S. manufacturing capacity for its Discovery Labware products, including BD Falcon™ products. The $25 million capital investment project is expected to create 28 new positions in 2007 and a total of 100 by the end of 2008, building on a presence of approximately 285 employees today.

With leading expertise in fluid handling, tissue culture, and cell screening, BD Biosciences - Discovery Labware provides products and services with applications for drug discovery, high throughput screening, angiogenesis and tumor invasion. The new capacity is intended to meet growing demand for BD Falcon™ tubes, pipettes, plates, cell inserts, and other products used in life science research settings.Approximately 50,000 square feet of manufacturing space will be added, directly contiguous to existing production lines.

“Treyburn offers an ideal platform as BD looks to increase capacity to meet demand for our Discovery Labware products,” said Todd Shackett, Plant Manager of the Treyburn facility. “We are able to build upon our own successful manufacturing operations, as well as the pool of high-tech expertise in this region. We couldn’t be more pleased to be growing in Durham. Today’s moves will provide the cornerstone for future development.”

Bill Kozy, Executive Vice President, added: “This expansion will allow BD to meet growing demand for class-leading products that are critical tools for life science researchers everywhere, while also enabling us to optimize our global production and supply chains for related products.”

Originally constructed in the mid-1980s, Treyburn was designated as a Labware production facility in 1991.Technologies deployed in BD’s highly specialized manufacturing in Treyburn include injection molding, blow molding, extrusion, plasma treating, printing, assembling, blister packaging, ultrasonic welding, membrane attachment, and DNASE-free cleanroom manufacturing.New lines and capacity have been added periodically since 1991.

About BD

BD, a leading global medical technology company that manufactures and sells medical devices, instrument systems and reagents, is dedicated to improving people’s health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 27,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. For more information, please visit www.bd.com.

***

This press release contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD’s performance, including future revenues, earnings per share and income, or events or developments that BD expects to occur or anticipates occurring in the future.All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. with respect to forward-looking statements contained herein, factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; changes in interest or foreign currency exchange rates; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; further increases in energy costs and their effect on, among other things, the cost of producing BD’s products; fluctuations in costs and availability of raw materials and in BD’s ability to maintain favorable supplier arrangements and relationships; uncertainties of litigation (as described in BD’s filings with the Securities and Exchange Commission); the effects of potential pandemic diseases; changes in healthcare or other governmental regulation; and issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD’s filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements.